6 Pharmaceutical Stocks to Buy Now

This week, six pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, GW Pharmaceuticals PLC Sponsored ADR’s (GWPH) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Lipocine, Inc. (LPCN) is seeing ratings go up from a C last week to a B this week. Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

The rating of Cardiome Pharma (CRME) moves up this week, rising from a C to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. Shares of the stock have been changing hands at an unusually rapid pace, four times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This week, AbbVie, Inc.’s (ABBV) ratings are up from a C last week to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/03/6-pharmaceutical-stocks-to-buy-now-path-gwph-wpi/.

©2021 InvestorPlace Media, LLC